DDInter1291 DDInter1544
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981.
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Nifedipine {u} (Compound) resembles {v} (Compound) Isradipine
Nifedipine {u} (Compound) resembles {v} (Compound) Nicardipine
Nifedipine {u} (Compound) treats {v} (Disease) hypertension
Nifedipine {u} (Compound) binds {v} (Gene) CALM1
Nifedipine {u} (Compound) upregulates {v} (Gene) MTHFD2
Nifedipine {u} (Compound) palliates {v} (Disease) systemic scleroderma
Nifedipine {u} (Compound) is included by {v} (Pharmacologic Class) Dihydropyridines
Nifedipine {u} (Compound) downregulates {v} (Gene) FOXO4
Nifedipine {u} (Compound) causes {v} (Side Effect) Sleep disorder
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Nifedipine (Compound) resembles Isradipine (Compound)
Nifedipine (Compound) resembles Nicardipine (Compound)
Nifedipine (Compound) treats hypertension (Disease)
Nifedipine (Compound) binds CALM1 (Gene)
Nifedipine (Compound) upregulates MTHFD2 (Gene)
Nifedipine (Compound) palliates systemic scleroderma (Disease)
Nifedipine (Compound) is included by Dihydropyridines (Pharmacologic Class)
Nifedipine (Compound) downregulates FOXO4 (Gene)
Nifedipine (Compound) causes Sleep disorder (Side Effect)
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide